CA2016704C - Apparatus and assay method for gamma glutamyltransferase (ggt) in liquid and dried whole blood - Google Patents
Apparatus and assay method for gamma glutamyltransferase (ggt) in liquid and dried whole bloodInfo
- Publication number
- CA2016704C CA2016704C CA 2016704 CA2016704A CA2016704C CA 2016704 C CA2016704 C CA 2016704C CA 2016704 CA2016704 CA 2016704 CA 2016704 A CA2016704 A CA 2016704A CA 2016704 C CA2016704 C CA 2016704C
- Authority
- CA
- Canada
- Prior art keywords
- gamma
- group
- mixture
- ggt
- nitrite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 85
- 239000008280 blood Substances 0.000 title claims abstract description 85
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 title claims abstract description 62
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 title claims abstract description 62
- 238000003556 assay Methods 0.000 title description 10
- 239000007788 liquid Substances 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 35
- 230000000694 effects Effects 0.000 claims abstract description 30
- 239000012530 fluid Substances 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 239000000758 substrate Substances 0.000 claims abstract description 9
- 238000006149 azo coupling reaction Methods 0.000 claims abstract description 8
- 239000003599 detergent Substances 0.000 claims abstract description 4
- 239000002250 absorbent Substances 0.000 claims description 17
- 230000002745 absorbent Effects 0.000 claims description 17
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 14
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 12
- 230000003381 solubilizing effect Effects 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- MZNYWPRCVDMOJG-UHFFFAOYSA-N N-(1-naphthyl)ethylenediamine dihydrochloride Chemical compound [Cl-].[Cl-].C1=CC=C2C([NH2+]CC[NH3+])=CC=CC2=C1 MZNYWPRCVDMOJG-UHFFFAOYSA-N 0.000 claims description 8
- 239000011521 glass Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 6
- 235000010288 sodium nitrite Nutrition 0.000 claims description 6
- GEHMBYLTCISYNY-UHFFFAOYSA-N Ammonium sulfamate Chemical compound [NH4+].NS([O-])(=O)=O GEHMBYLTCISYNY-UHFFFAOYSA-N 0.000 claims description 5
- 235000011054 acetic acid Nutrition 0.000 claims description 5
- 125000002642 gamma-glutamyl group Chemical group 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 claims description 4
- 235000010289 potassium nitrite Nutrition 0.000 claims description 4
- 239000004304 potassium nitrite Substances 0.000 claims description 4
- 229920003043 Cellulose fiber Polymers 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 3
- 239000005909 Kieselgur Substances 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 150000001243 acetic acids Chemical class 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 230000002949 hemolytic effect Effects 0.000 claims description 3
- 235000011007 phosphoric acid Nutrition 0.000 claims description 3
- 235000011044 succinic acid Nutrition 0.000 claims description 3
- 235000010338 boric acid Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 claims 4
- JBIJLHTVPXGSAM-UHFFFAOYSA-N 2-naphthylamine Chemical compound C1=CC=CC2=CC(N)=CC=C21 JBIJLHTVPXGSAM-UHFFFAOYSA-N 0.000 claims 2
- ZBIBQNVRTVLOHQ-UHFFFAOYSA-N 5-aminonaphthalen-1-ol Chemical compound C1=CC=C2C(N)=CC=CC2=C1O ZBIBQNVRTVLOHQ-UHFFFAOYSA-N 0.000 claims 2
- QYFYIOWLBSPSDM-UHFFFAOYSA-N 6-aminonaphthalen-1-ol Chemical compound OC1=CC=CC2=CC(N)=CC=C21 QYFYIOWLBSPSDM-UHFFFAOYSA-N 0.000 claims 2
- HMNPDEGBVWDHAR-UHFFFAOYSA-N 8-aminonaphthalen-1-ol Chemical compound C1=CC(O)=C2C(N)=CC=CC2=C1 HMNPDEGBVWDHAR-UHFFFAOYSA-N 0.000 claims 2
- 239000007975 buffered saline Substances 0.000 claims 1
- 239000000123 paper Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 13
- 239000007795 chemical reaction product Substances 0.000 abstract description 9
- 238000006911 enzymatic reaction Methods 0.000 abstract description 9
- 239000000243 solution Substances 0.000 abstract description 8
- 238000004458 analytical method Methods 0.000 abstract description 7
- 238000005119 centrifugation Methods 0.000 abstract description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 abstract description 2
- 239000002953 phosphate buffered saline Substances 0.000 abstract description 2
- 230000006920 protein precipitation Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 47
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 14
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 108010008488 Glycylglycine Proteins 0.000 description 7
- 229940043257 glycylglycine Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 150000008049 diazo compounds Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- WZVXLJYENHHFPD-UHFFFAOYSA-N methylaminomethanol;hydrochloride Chemical compound Cl.CNCO WZVXLJYENHHFPD-UHFFFAOYSA-N 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 101001003194 Eleusine coracana Alpha-amylase/trypsin inhibitor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 125000005619 boric acid group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/52—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving transaminase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91045—Acyltransferases (2.3)
- G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A method of gamma glutamyltransferase (GGT) analysis is suitable for use with hemolyzed fluid or dried whole blood samples which avoids the need for protein precipitation or centrifugation of the sample. Analysis is by first mixing a fluid or dried whole blood sample with a phosphate buffered saline solution containing a non-ionic biological detergent.
The mixture is then vigorously agitated for one hour at room temperature. The activity of the GGT is then determined by reacting the mixture with a GGT substrate. Color is developed by a diazo coupling reaction with the enzyme reaction product.
The intensity of the color is then measured.
The mixture is then vigorously agitated for one hour at room temperature. The activity of the GGT is then determined by reacting the mixture with a GGT substrate. Color is developed by a diazo coupling reaction with the enzyme reaction product.
The intensity of the color is then measured.
Description
~ 2016~0~
APP~RATI~S ~ND ASSAY METH~D FOR GAMMA
GLuTAMyLTRANsFERAsE (GGT) IN LIQUID AND DRIED WHOLE ~LOO~
FIELD OF THE INVENTION
This invention relates to improvements in an apparatus for transporting whole blood samples and a method to assay for gan~a glutamyltransferase (GGT) actLvity in such whole blood samples. In particular, this invention provides an apparatus for transporting samples of dried whole blood, and a method for analysis of GGT in samples of dried or fluld whole blood which may exhibit partial or complete hemolysis.
BACKGROUND OF THE INVENTION
The enzyme gamma glutamyltransferase (GGT) catalyses the transfer of a gamma glutamyl moiety to an amino acid or peptide. The enzyme is present in the liver, kidney, prostate, pancreas, blood and other tissues. GGT is believed to be part of the glutathione cycle.
Elevation of the blood GGT level has been demonstrated to be an indicator of various diseases.
Initially, the elevation of the blood GGT level, as measured by increased GGT activity in blood samples, was used as a test for diseases of the liver, bile ducts, and pancreas. It has since become commonly used as a general indicator of liver disorder. Increased blood GGT activity is indicative of liver dysfunction and may indicate pathology due to high alcohol consumption, drug use or disease. Elevated GGT activity has also been noted in conjunction with other diseases such as -~ ZC~67(:! ~
myocardial infarction, pancreatitis, and intra-cerebral tumors.
Currently, the amount of GGT present in blood is cornmonly measured using a kinetic assay on blood serum wherein (gamma-L-glutamyl)-p-nitroanilide and glycylglycine are the substrates for the GGT enzymatic formation of p-nitroaniline.
The suhstrates are allowed to react with serum GGT for approximately 10 minutes. The p-nitroaniline produced in this reaction is then measured spectrophotometrically in the wavelength range of 405-410 nm. The rate of p-nitroaniline formation is proportional to GGT activity. Therefore, a high conversion to p-nitroaniline is indicative of a high GGT
concentration in the serum, which may be due to liver degradation.
This method, however, is not applicable to analysis of blood samples in which the red blood cells have been ruptured or hemolysed. Any disruption of red blood cells prior to testing will interfere with an accurate determination of GGT activity, due to the strong light absorption by hemoglobin in the wavelength range used to observe the formation of p-nitroaniline. Methods of analysis have been developed to deal with the presence of hemoglobin in the sample. These methods involve post-reaction precipitation of blood protein by trichloroacetic acid followed by centrifugation of the sample. While this procedure avoids heMoglobin interference 201~7~
f~ , it retalns the need for a large fluid blood sample volume that must be obtained from the suh~ect and adds additional steps to the assay procedure.
An alternative to direct measurement of the p-nitroaniline is a method in which the GGT enzyme reaction product, p-nitroaniline, is diazotized and coupled with a chromophore to produce a mixture more suitable for spectrophotometric analysis. This method, however, utilizes blood serum and is not applicable to w~lole blood samples or samples of dried blood as is the method of the present invention.
Presently available assay methods which utilize fluid blood serum samples for determination of GGT activity are ineffective when blood sample damage has occurred during shipping. Sample damage may result in hemolysis or enzyme denaturation with subsequent enzyme activity loss. In addition, leaking fluid sample packages create a potential health hazard for personnel who are required to handle packages containing fluid blood, physiological fluids, or chemical reagents.
Analysis of GGT activity in blood is being employed by insurers to determine the desirability of offering insurance contracts to potential customers. This use is increasing the submission of physiological fluid samples, such as blood or urine, to laboratories from persons residing far 20~6~
from the laboratory. The advent of such distant sampling presents a number of problems in assaying for GGT actlvity.
Conveyance of theqe s~mples to the laboratory often occurs under poor conditions. Mistreatment of blood samples and concomitant rupture of red blo~d cells introduces hemoglobin into the sample resulting in interference with the current GGT
assay procedures. The use of public and private mail delivery systems to transport such samples increases the potential for careless handl.ing. Damaged and leaking fluid samples may alarm or endanger mail system workers who contact the damaged and leaking packages of blood or other fluid physiological materials. Finally, mishandling of blood samples may cause a loss of GGT activity due to denaturation of the GGT enzyme and result in unreliable test results.
OBJECTS OF THE INVENTION
It is, therefore, an important object of the present invention to provide a method and apparatus to obtain GGT and to assay for GGT activity in whole blood which is independent of fluid sample ~ollection techniques and the problems of sample container integrity and fluid sample damage presented by transporting fluid blood samples.
Another important object of the present invention is to provide a method of assaying for GGT activity in whole blood which does not require prior separation of the blood _5_ 7 f~ 7 ~J ~
serum or precipitation of the blood proteins and is unaffected by the presence of hemolytic contAm;n~nts in the test sample.
Furthermore, it i8 an important objective of this invention to provide a method and apparatus to obtain and assay for GGT activity which can utilize a convenient and stable sample means to convey the blood sample to the laboratory and thereby avoid the previous fluid sample transportation difficulties while providing greater protection for transportation employees and laboratory personnel from potentially harmful components associated with fluid biological samples of unknown origin.
In a broad aspect, therefore, the present invention relates to a method of assaying the activity of gamma glutamyltransferase (GGT) obtained from a blood sample which comprises: applying a fluid, whole blood sample or fluid, hemolytic sample to a means ~or absorbent support; drying the blood sample on the means for absorbent support to produce a dried blood sample; dissolving the GGT contained in the dried blood sample by combining a quantity of the dried blood sample with a means for solubilizing the dried blood sample to produce a first mixture such that the mA~imum dilution of the fluid blood sample volume in the solubilizing means is about 1:60;
reacting for a time in excess of one-half hour a portion of the first mixture with a gamma glutamyltransferase substrate and a gamma glutamyl acceptor to produce a second mixture; adding to the second mi~ture aqueous solutions of an acid, a nitrite source, a means for accepting excess nitrite, and a means for -5a- 2016704 diazo coupling, in sufficient relative quantities to produce a colored final mixture; and measuring the color intensity of the final mixture at a wavelength in the range of 475 to 600 nanometers, said color intensity being proportional to enzyme activity.
In another broad aspect, therefore, the present invention relates to a method of assaying the activity of gamma glutamyltransferase in a sample of whole blood which comprises:
reacting for a time in excess of one-half hour whole blood with a gamma glutamyltransferase substrate and a gamma glutamyl acceptor to produce a mixture; adding to the mixture aqueous solution of an acid, a nitrite source, a means for accepting excess nitrite, and a means for diazo coupling, in sufficient relative quantities to produce a colored final mixture; and measuring the color intensity of the final mixture at a wavelength in the range o~ 475 to 600 nanometers, said color intensity being proportional to enzyme activity.
Other objects and advantages of this invention will become apparent from the following description, wherein is set forth by way of illustration and example, an embodiment of this invention.
DESCRIPTION OF THE PREFERRED EMBODIMENT
The present invention is adapted to utilizing a sample of fluid or dried or partially dried whole blood from which is obtained GGT. The GGT is obtained in a manner which retains substantial enzyme activity. In using dried blood as the source A
~ 20~ 6704 -5b-for GGT, the problems of leaking packages endangering personnel as well as blood sample damage resulting from careless handling by transport workers are avoided. As separation of the blood serum is not required for operation of the inventive method, small quantities of fluid whole blood ` 2~)167Q4;
.
may act as the source for GGT. The sample volume of blood required for transport may be so substantially reduced as to avoid the dangers presented by shipment of the relatively large volumes of fluid blood required in GGT assays which involve separation of the blood serum prior to testing.
The method of analysis of GGT activity contained herein also avoids the interference previously presented by the presence of hemoglobin in the blood sample and thus reduces tlle nee~ for careful handling of the sample during transportation to the laboratory.
One embodiment of the invention utilizes a whole blood specimen which is applied to an absorbent support means.
The absorbent support means may be such that the blood sample may either adhere to the surfaces of the support means, or alternatively be taken into the body of the support means. By way of example, and not limitation, blood may be absorbed onto the surface of a sheet of glass. Alternatively, blood may be absorbed into a cotton pad or absorbed into a volume of diatomaceous earth.
A predetermined quantity of blood may be applied to the absorbent support means or the absorbent support means may be such that it will absorb a known quantity of blood either by volume, weight, or surface area of the absorbent support means. Alternatively, an unmeasured amount of blood may be applied to the absorbent support means for later 201670~
quantification. Examples of acceptable absorbent support means are cellulose fiber such as paper or cotton fiber, or glass, fritted glass, or diatomaceous earth, with a cellulose fiber such as paper being the preferred embodiment. Other well-known absorbent means are equally satisfactory as a structure to hold the blood sample.
The blood sample so applied to the absorbent support means is then dried while remaining in contact with the absorbent support means. The assay method of the invention may be used with such dried blood samples even though the manner of sample collection or subsequent drying or transportation has resulted in complete hemolysis of the blood sample.
After absorption and drying of the blood sample, a dried blood hemolysate is prepared by adding a quantity of the dried blood sample to a solubilizing means and the resultant mixture may then be vigorously agitated to aid solubilization.
The dried blood may be either first separated from the absol^bent means or left in contact with the absorbent means during solubilization. The solubilizing means may be a volume of water or saline solution and may include a buffer system to maintain a substantially constant pH. A quantity of a non-ionic biological detergent may also be added to the solubilizing means to facilitate solubilization. The quantity of the solubilizing means combined with the dried blood is 20167~
~ -8-sufficient so as to result in a dilution of the original fluid blood sample volume to a ratio as low as 1:60. The buffer system may be selected from phosphoric, citric, formic, boric, acetic, and succinic acids or any available and convenient buffer system that would provide a substantially constant pH
and non-absorbance in the wavelength range selected for the colorimetric determination. Examples of non-ionic detergents which may be used in the above methods are octylphenol-ethylene oxide (Nonidet P-40~), polyoxyethylene et.hers (BRIJ~), polyoxyethylenesorbitan (TWEEN~), sorbitan (SPAN~), or Triton X-100~ (octylphenylpoly [ethylene glycol et,her]n) -A volume of the dried blood hemolysate is then added to an approximately ten fold greater volume of a GGT substrate such as (gamma-L-glutamyl)-p-nitroanilide. This mixture is then allowed to react for a time greater than one-half hour.
l'he reaction time may be as short as one-half hour or allowed to continue overnight, however, a reaction time of two hours is optimal for the development of color in samples exhibiting low enzyme activity. Room temperature is compatible with consistent results. If the reaction is to continue for many hours a reduction in the temperature to a range of 2-8C is preferable. The optimal reaction temperature is approximately 37 centigrade.
20~67Q~
Upon termination of the reaction period, color development in the sample is achieved by addition of a volume of an aqueous acid; a volume of a nitrite source; a volume of an acceptor for excess nitrite; and a volume of a diazo coupling means to form the diazo derivative of the GGT enzyme reaction product in the mixture. Color in the te~t sample develops rapidly and a spectrophotometric reading may then be obtained in the wavelength range of 475 nm to 600 nm.
In one example of this preferred embodiment the whole blood was applied to thick absorbent paper and allowed to dry. A disk, one-quarter inch in diameter, was then punched from the paper. The dried blood hemolysate was then prepared by soaking the disk in O.lOOml of phosphate-buffered saline of pH 7.4, containing 0.5% Triton X-100~, at room temperature for one hour witll vigorous agitation. A 0.025ml volume of the hemolysate was then added to 0.250ml of a saturated solution of (gamma-L-glutamyl)-p-nitroanilide in O.lM TRIS~ [(hydroxymethyl) aminomethane hydrochloride] at pH
8.2 and made in O.lM glycylglycine. This solution was incubated ~or 120 minutes at 37 centigrade. At the conclusion of the reaction period, l.Oml of 10% acetic acid, 0.5ml of 0.1% sodium nitrite, 0.5ml of 0.5% ammonium sulfamate, and 0.5ml of 0.1% N-(1-naphthyl) ethylenediamine dihydrochloride were added to the reaction mixture to diazotize the enzyme reaction end-product p-nitroaniline. The Z016~
color intensity of the resulting diazo compound chromophore was observed at wavelength 540nm. The degree of color intensity was proportional to the degree of GGT activity in the sample.
In a second example of the preferred embodiment a fluid blood sample was applied to the interior walls of a .
glass vial and allowed to dry upon the walls and interior base of the glass vial. The dried blood hemolysate was then prepared by adding to the vial 0.200ml of water and allowing the blood to dissolve in the water without agitation. A
0.025ml volume of the hemolysate was then added to 0.250ml of a saturated solution of (gamma-L-glutamyl)-p-nitroanilide in O.lM TRIS~ [(hydroxymethyl) aminomethane hydrochloride] at p~I
8.2 and made in O.lM glycylglycine. This solution was incubated overnight at room temperature. At the conclusion of the reaction, l.Oml of lN hydrochloric acid, 0.5ml of 0.1%
potassium nitrite, 0.5ml of 0.5% ammonium sulfamate, and 0.5ml of 0.1~ N-(l-naphthyl) ethylenediamine dihydrochloride were added to the reaction mixture to create the diazo derivative of the enzyme reaction end-product. The color intensity of the resulting diazo compound chromophore was then measured at wavelength S75nm. The degree of absorption was proportional to the degree of GGT activity in the sample.
In a third example of the preferred embodiment a kllown volume of blood was added to a small quantity of 20167~
diat~maceous earth and allowed to dry. The dried blood hemolysate was then prepared by the addition of 0.200ml of saline of pH 6.0 with agitation. A 0.025ml volume of the hemolysate was added to 0.250ml of a 0.007 molar ~olution of (gamma-L-glutamyl)-3-carboxy-p-nitroanilide in O.lM TRIS~
[(~Iydroxymethyl) aminomethane hydrochloride] at pH 8.2 and made in O.lM glycylglycine. This solution was incubated for one hour at 37 centigrade. At the conclusion of the reaction, l.Oml of lN hydrochloric acid, 0.5ml of 0.1% sodium nitrite, 0.5ml of 0.5% sulfamic acid, and 0.5ml of 0.05%
N-(l-naphthyl) ethylenediamine dihydrochloride were added to the reaction mixture to diazotize the enzyme reaction end-product. The color intensity of the resulting diazo compouIId chromophore was then observed at wavelength 500nm.
The degree of absorption was proportional to the degree of GGT
activity in the sample.
An alternative embodiment of the invention utilizes small volumes of whole blood in either fluid form or partially dehydrated form. In one example of this preferred embodiment whole blood was added to 0.250ml of a saturated solution of (gamma-L-glutamyl)-p-nitroanilide in O.lM TRIS~
[(hydroxymethyl) aminomethane hydrochloride] at pH 8.2 and made in O.lM glycylglycine. This solution was incubated for 120 minutes at 37 centigrade. At the conclusion of the reaction period, l.Oml of 10% acetic acid, 0.5ml of 0.1%
~016~
sodium nitrite, 0.5ml of 0.5% a~nonium sulfamate, and 0.5ml of 0.1% N-(l-naphthyl) ethylenediamine dihydrochloride were added to the reaction mixture to diazotize the enzyme reaction end-product p-nitroaniline. The color intensity of the resulting diazo compound chromophore was observed at wavelength 540nm. The degree of color intensity was proportional to the degree of GGT activity in the sample.
In a second example of this alternative embodiment a fluid whole blood sample was added to 0.250ml of a saturated solution of (gamma-L-glutamyl)-p-nitroanilide in O.lM TRIS~
[(hydroxymet}lyl) aminomethane hydrochloride] at pH 8.2 and nlade in O.lM glycylglycine. This solution was incubated for 90 minutes at 37 centigrade. At the conclusion of the reaction, l.Oml of lN hydrochloric acid, 0.5ml of 0.1%
potassium nitrite, 0.5ml of 0.5~ ammonium sulfamate, and 0.5ml of 0.1% N-(l-naphthyl) ethylenediamine dihydrochloride were added to the reaction mixture to create the diazo derivative of the enzyme reaction end-product. The color intensity of the resulting diazo compound chromophore was then measured at wavelength 575nm. The degree of absorption was proportional tv the degree of GGT activity in the sample.
In a third example of this alternative embodiment fluid whole blood was added to 0.250ml of a 0.007 molar solution of (gamma-L-glutamyl)-3-carboxy-p-nitroanilide in O.lM TRIS~ [(hydroxymethyl) aminomethane hydrochloride] at pH
Z0167~
8.2 and made in O.lM glycylglycine. lhis solution was incubated for one hour at 37 centigrade. At the conclusion of the reaction, l.Oml of lN hydrochloric acid, 0.5ml of 0.1%
sodium nitrite, 0.5ml of 0.5% sulfamic acid, and 0.5ml of 0.05% N-(l-naphthyl) ethylenediamine dihydrochloride were added to the reaction mixture to diazotize the enzyme reaction end-product. The color intensity of the resulting diazo compound chromophore was then observed at wavelength 500nm.
The degree of absorption was proportional to the degree of GGT
activity in the sample.
It is to be understood that while certain forms of this invention have been illustrated and described, it is not limited thereto, except insofar as such limitations are included in the followiIlg claims.
APP~RATI~S ~ND ASSAY METH~D FOR GAMMA
GLuTAMyLTRANsFERAsE (GGT) IN LIQUID AND DRIED WHOLE ~LOO~
FIELD OF THE INVENTION
This invention relates to improvements in an apparatus for transporting whole blood samples and a method to assay for gan~a glutamyltransferase (GGT) actLvity in such whole blood samples. In particular, this invention provides an apparatus for transporting samples of dried whole blood, and a method for analysis of GGT in samples of dried or fluld whole blood which may exhibit partial or complete hemolysis.
BACKGROUND OF THE INVENTION
The enzyme gamma glutamyltransferase (GGT) catalyses the transfer of a gamma glutamyl moiety to an amino acid or peptide. The enzyme is present in the liver, kidney, prostate, pancreas, blood and other tissues. GGT is believed to be part of the glutathione cycle.
Elevation of the blood GGT level has been demonstrated to be an indicator of various diseases.
Initially, the elevation of the blood GGT level, as measured by increased GGT activity in blood samples, was used as a test for diseases of the liver, bile ducts, and pancreas. It has since become commonly used as a general indicator of liver disorder. Increased blood GGT activity is indicative of liver dysfunction and may indicate pathology due to high alcohol consumption, drug use or disease. Elevated GGT activity has also been noted in conjunction with other diseases such as -~ ZC~67(:! ~
myocardial infarction, pancreatitis, and intra-cerebral tumors.
Currently, the amount of GGT present in blood is cornmonly measured using a kinetic assay on blood serum wherein (gamma-L-glutamyl)-p-nitroanilide and glycylglycine are the substrates for the GGT enzymatic formation of p-nitroaniline.
The suhstrates are allowed to react with serum GGT for approximately 10 minutes. The p-nitroaniline produced in this reaction is then measured spectrophotometrically in the wavelength range of 405-410 nm. The rate of p-nitroaniline formation is proportional to GGT activity. Therefore, a high conversion to p-nitroaniline is indicative of a high GGT
concentration in the serum, which may be due to liver degradation.
This method, however, is not applicable to analysis of blood samples in which the red blood cells have been ruptured or hemolysed. Any disruption of red blood cells prior to testing will interfere with an accurate determination of GGT activity, due to the strong light absorption by hemoglobin in the wavelength range used to observe the formation of p-nitroaniline. Methods of analysis have been developed to deal with the presence of hemoglobin in the sample. These methods involve post-reaction precipitation of blood protein by trichloroacetic acid followed by centrifugation of the sample. While this procedure avoids heMoglobin interference 201~7~
f~ , it retalns the need for a large fluid blood sample volume that must be obtained from the suh~ect and adds additional steps to the assay procedure.
An alternative to direct measurement of the p-nitroaniline is a method in which the GGT enzyme reaction product, p-nitroaniline, is diazotized and coupled with a chromophore to produce a mixture more suitable for spectrophotometric analysis. This method, however, utilizes blood serum and is not applicable to w~lole blood samples or samples of dried blood as is the method of the present invention.
Presently available assay methods which utilize fluid blood serum samples for determination of GGT activity are ineffective when blood sample damage has occurred during shipping. Sample damage may result in hemolysis or enzyme denaturation with subsequent enzyme activity loss. In addition, leaking fluid sample packages create a potential health hazard for personnel who are required to handle packages containing fluid blood, physiological fluids, or chemical reagents.
Analysis of GGT activity in blood is being employed by insurers to determine the desirability of offering insurance contracts to potential customers. This use is increasing the submission of physiological fluid samples, such as blood or urine, to laboratories from persons residing far 20~6~
from the laboratory. The advent of such distant sampling presents a number of problems in assaying for GGT actlvity.
Conveyance of theqe s~mples to the laboratory often occurs under poor conditions. Mistreatment of blood samples and concomitant rupture of red blo~d cells introduces hemoglobin into the sample resulting in interference with the current GGT
assay procedures. The use of public and private mail delivery systems to transport such samples increases the potential for careless handl.ing. Damaged and leaking fluid samples may alarm or endanger mail system workers who contact the damaged and leaking packages of blood or other fluid physiological materials. Finally, mishandling of blood samples may cause a loss of GGT activity due to denaturation of the GGT enzyme and result in unreliable test results.
OBJECTS OF THE INVENTION
It is, therefore, an important object of the present invention to provide a method and apparatus to obtain GGT and to assay for GGT activity in whole blood which is independent of fluid sample ~ollection techniques and the problems of sample container integrity and fluid sample damage presented by transporting fluid blood samples.
Another important object of the present invention is to provide a method of assaying for GGT activity in whole blood which does not require prior separation of the blood _5_ 7 f~ 7 ~J ~
serum or precipitation of the blood proteins and is unaffected by the presence of hemolytic contAm;n~nts in the test sample.
Furthermore, it i8 an important objective of this invention to provide a method and apparatus to obtain and assay for GGT activity which can utilize a convenient and stable sample means to convey the blood sample to the laboratory and thereby avoid the previous fluid sample transportation difficulties while providing greater protection for transportation employees and laboratory personnel from potentially harmful components associated with fluid biological samples of unknown origin.
In a broad aspect, therefore, the present invention relates to a method of assaying the activity of gamma glutamyltransferase (GGT) obtained from a blood sample which comprises: applying a fluid, whole blood sample or fluid, hemolytic sample to a means ~or absorbent support; drying the blood sample on the means for absorbent support to produce a dried blood sample; dissolving the GGT contained in the dried blood sample by combining a quantity of the dried blood sample with a means for solubilizing the dried blood sample to produce a first mixture such that the mA~imum dilution of the fluid blood sample volume in the solubilizing means is about 1:60;
reacting for a time in excess of one-half hour a portion of the first mixture with a gamma glutamyltransferase substrate and a gamma glutamyl acceptor to produce a second mixture; adding to the second mi~ture aqueous solutions of an acid, a nitrite source, a means for accepting excess nitrite, and a means for -5a- 2016704 diazo coupling, in sufficient relative quantities to produce a colored final mixture; and measuring the color intensity of the final mixture at a wavelength in the range of 475 to 600 nanometers, said color intensity being proportional to enzyme activity.
In another broad aspect, therefore, the present invention relates to a method of assaying the activity of gamma glutamyltransferase in a sample of whole blood which comprises:
reacting for a time in excess of one-half hour whole blood with a gamma glutamyltransferase substrate and a gamma glutamyl acceptor to produce a mixture; adding to the mixture aqueous solution of an acid, a nitrite source, a means for accepting excess nitrite, and a means for diazo coupling, in sufficient relative quantities to produce a colored final mixture; and measuring the color intensity of the final mixture at a wavelength in the range o~ 475 to 600 nanometers, said color intensity being proportional to enzyme activity.
Other objects and advantages of this invention will become apparent from the following description, wherein is set forth by way of illustration and example, an embodiment of this invention.
DESCRIPTION OF THE PREFERRED EMBODIMENT
The present invention is adapted to utilizing a sample of fluid or dried or partially dried whole blood from which is obtained GGT. The GGT is obtained in a manner which retains substantial enzyme activity. In using dried blood as the source A
~ 20~ 6704 -5b-for GGT, the problems of leaking packages endangering personnel as well as blood sample damage resulting from careless handling by transport workers are avoided. As separation of the blood serum is not required for operation of the inventive method, small quantities of fluid whole blood ` 2~)167Q4;
.
may act as the source for GGT. The sample volume of blood required for transport may be so substantially reduced as to avoid the dangers presented by shipment of the relatively large volumes of fluid blood required in GGT assays which involve separation of the blood serum prior to testing.
The method of analysis of GGT activity contained herein also avoids the interference previously presented by the presence of hemoglobin in the blood sample and thus reduces tlle nee~ for careful handling of the sample during transportation to the laboratory.
One embodiment of the invention utilizes a whole blood specimen which is applied to an absorbent support means.
The absorbent support means may be such that the blood sample may either adhere to the surfaces of the support means, or alternatively be taken into the body of the support means. By way of example, and not limitation, blood may be absorbed onto the surface of a sheet of glass. Alternatively, blood may be absorbed into a cotton pad or absorbed into a volume of diatomaceous earth.
A predetermined quantity of blood may be applied to the absorbent support means or the absorbent support means may be such that it will absorb a known quantity of blood either by volume, weight, or surface area of the absorbent support means. Alternatively, an unmeasured amount of blood may be applied to the absorbent support means for later 201670~
quantification. Examples of acceptable absorbent support means are cellulose fiber such as paper or cotton fiber, or glass, fritted glass, or diatomaceous earth, with a cellulose fiber such as paper being the preferred embodiment. Other well-known absorbent means are equally satisfactory as a structure to hold the blood sample.
The blood sample so applied to the absorbent support means is then dried while remaining in contact with the absorbent support means. The assay method of the invention may be used with such dried blood samples even though the manner of sample collection or subsequent drying or transportation has resulted in complete hemolysis of the blood sample.
After absorption and drying of the blood sample, a dried blood hemolysate is prepared by adding a quantity of the dried blood sample to a solubilizing means and the resultant mixture may then be vigorously agitated to aid solubilization.
The dried blood may be either first separated from the absol^bent means or left in contact with the absorbent means during solubilization. The solubilizing means may be a volume of water or saline solution and may include a buffer system to maintain a substantially constant pH. A quantity of a non-ionic biological detergent may also be added to the solubilizing means to facilitate solubilization. The quantity of the solubilizing means combined with the dried blood is 20167~
~ -8-sufficient so as to result in a dilution of the original fluid blood sample volume to a ratio as low as 1:60. The buffer system may be selected from phosphoric, citric, formic, boric, acetic, and succinic acids or any available and convenient buffer system that would provide a substantially constant pH
and non-absorbance in the wavelength range selected for the colorimetric determination. Examples of non-ionic detergents which may be used in the above methods are octylphenol-ethylene oxide (Nonidet P-40~), polyoxyethylene et.hers (BRIJ~), polyoxyethylenesorbitan (TWEEN~), sorbitan (SPAN~), or Triton X-100~ (octylphenylpoly [ethylene glycol et,her]n) -A volume of the dried blood hemolysate is then added to an approximately ten fold greater volume of a GGT substrate such as (gamma-L-glutamyl)-p-nitroanilide. This mixture is then allowed to react for a time greater than one-half hour.
l'he reaction time may be as short as one-half hour or allowed to continue overnight, however, a reaction time of two hours is optimal for the development of color in samples exhibiting low enzyme activity. Room temperature is compatible with consistent results. If the reaction is to continue for many hours a reduction in the temperature to a range of 2-8C is preferable. The optimal reaction temperature is approximately 37 centigrade.
20~67Q~
Upon termination of the reaction period, color development in the sample is achieved by addition of a volume of an aqueous acid; a volume of a nitrite source; a volume of an acceptor for excess nitrite; and a volume of a diazo coupling means to form the diazo derivative of the GGT enzyme reaction product in the mixture. Color in the te~t sample develops rapidly and a spectrophotometric reading may then be obtained in the wavelength range of 475 nm to 600 nm.
In one example of this preferred embodiment the whole blood was applied to thick absorbent paper and allowed to dry. A disk, one-quarter inch in diameter, was then punched from the paper. The dried blood hemolysate was then prepared by soaking the disk in O.lOOml of phosphate-buffered saline of pH 7.4, containing 0.5% Triton X-100~, at room temperature for one hour witll vigorous agitation. A 0.025ml volume of the hemolysate was then added to 0.250ml of a saturated solution of (gamma-L-glutamyl)-p-nitroanilide in O.lM TRIS~ [(hydroxymethyl) aminomethane hydrochloride] at pH
8.2 and made in O.lM glycylglycine. This solution was incubated ~or 120 minutes at 37 centigrade. At the conclusion of the reaction period, l.Oml of 10% acetic acid, 0.5ml of 0.1% sodium nitrite, 0.5ml of 0.5% ammonium sulfamate, and 0.5ml of 0.1% N-(1-naphthyl) ethylenediamine dihydrochloride were added to the reaction mixture to diazotize the enzyme reaction end-product p-nitroaniline. The Z016~
color intensity of the resulting diazo compound chromophore was observed at wavelength 540nm. The degree of color intensity was proportional to the degree of GGT activity in the sample.
In a second example of the preferred embodiment a fluid blood sample was applied to the interior walls of a .
glass vial and allowed to dry upon the walls and interior base of the glass vial. The dried blood hemolysate was then prepared by adding to the vial 0.200ml of water and allowing the blood to dissolve in the water without agitation. A
0.025ml volume of the hemolysate was then added to 0.250ml of a saturated solution of (gamma-L-glutamyl)-p-nitroanilide in O.lM TRIS~ [(hydroxymethyl) aminomethane hydrochloride] at p~I
8.2 and made in O.lM glycylglycine. This solution was incubated overnight at room temperature. At the conclusion of the reaction, l.Oml of lN hydrochloric acid, 0.5ml of 0.1%
potassium nitrite, 0.5ml of 0.5% ammonium sulfamate, and 0.5ml of 0.1~ N-(l-naphthyl) ethylenediamine dihydrochloride were added to the reaction mixture to create the diazo derivative of the enzyme reaction end-product. The color intensity of the resulting diazo compound chromophore was then measured at wavelength S75nm. The degree of absorption was proportional to the degree of GGT activity in the sample.
In a third example of the preferred embodiment a kllown volume of blood was added to a small quantity of 20167~
diat~maceous earth and allowed to dry. The dried blood hemolysate was then prepared by the addition of 0.200ml of saline of pH 6.0 with agitation. A 0.025ml volume of the hemolysate was added to 0.250ml of a 0.007 molar ~olution of (gamma-L-glutamyl)-3-carboxy-p-nitroanilide in O.lM TRIS~
[(~Iydroxymethyl) aminomethane hydrochloride] at pH 8.2 and made in O.lM glycylglycine. This solution was incubated for one hour at 37 centigrade. At the conclusion of the reaction, l.Oml of lN hydrochloric acid, 0.5ml of 0.1% sodium nitrite, 0.5ml of 0.5% sulfamic acid, and 0.5ml of 0.05%
N-(l-naphthyl) ethylenediamine dihydrochloride were added to the reaction mixture to diazotize the enzyme reaction end-product. The color intensity of the resulting diazo compouIId chromophore was then observed at wavelength 500nm.
The degree of absorption was proportional to the degree of GGT
activity in the sample.
An alternative embodiment of the invention utilizes small volumes of whole blood in either fluid form or partially dehydrated form. In one example of this preferred embodiment whole blood was added to 0.250ml of a saturated solution of (gamma-L-glutamyl)-p-nitroanilide in O.lM TRIS~
[(hydroxymethyl) aminomethane hydrochloride] at pH 8.2 and made in O.lM glycylglycine. This solution was incubated for 120 minutes at 37 centigrade. At the conclusion of the reaction period, l.Oml of 10% acetic acid, 0.5ml of 0.1%
~016~
sodium nitrite, 0.5ml of 0.5% a~nonium sulfamate, and 0.5ml of 0.1% N-(l-naphthyl) ethylenediamine dihydrochloride were added to the reaction mixture to diazotize the enzyme reaction end-product p-nitroaniline. The color intensity of the resulting diazo compound chromophore was observed at wavelength 540nm. The degree of color intensity was proportional to the degree of GGT activity in the sample.
In a second example of this alternative embodiment a fluid whole blood sample was added to 0.250ml of a saturated solution of (gamma-L-glutamyl)-p-nitroanilide in O.lM TRIS~
[(hydroxymet}lyl) aminomethane hydrochloride] at pH 8.2 and nlade in O.lM glycylglycine. This solution was incubated for 90 minutes at 37 centigrade. At the conclusion of the reaction, l.Oml of lN hydrochloric acid, 0.5ml of 0.1%
potassium nitrite, 0.5ml of 0.5~ ammonium sulfamate, and 0.5ml of 0.1% N-(l-naphthyl) ethylenediamine dihydrochloride were added to the reaction mixture to create the diazo derivative of the enzyme reaction end-product. The color intensity of the resulting diazo compound chromophore was then measured at wavelength 575nm. The degree of absorption was proportional tv the degree of GGT activity in the sample.
In a third example of this alternative embodiment fluid whole blood was added to 0.250ml of a 0.007 molar solution of (gamma-L-glutamyl)-3-carboxy-p-nitroanilide in O.lM TRIS~ [(hydroxymethyl) aminomethane hydrochloride] at pH
Z0167~
8.2 and made in O.lM glycylglycine. lhis solution was incubated for one hour at 37 centigrade. At the conclusion of the reaction, l.Oml of lN hydrochloric acid, 0.5ml of 0.1%
sodium nitrite, 0.5ml of 0.5% sulfamic acid, and 0.5ml of 0.05% N-(l-naphthyl) ethylenediamine dihydrochloride were added to the reaction mixture to diazotize the enzyme reaction end-product. The color intensity of the resulting diazo compound chromophore was then observed at wavelength 500nm.
The degree of absorption was proportional to the degree of GGT
activity in the sample.
It is to be understood that while certain forms of this invention have been illustrated and described, it is not limited thereto, except insofar as such limitations are included in the followiIlg claims.
Claims (17)
1. A method of assaying the activity of gamma glutamyltransferase (GGT) obtained from a blood sample which comprises:
applying a fluid, whole blood sample or fluid, hemolytic sample to a means for absorbent support;
drying the blood sample on the means for absorbent support to produce a dried blood sample;
dissolving the GGT contained in the dried blood sample by combining a quantity of the dried blood sample with a means for solubilizing the dried blood sample to produce a first mixture such that the maximum dilution of the fluid blood sample volume in the solubilizing means is about 1:60;
reacting for a time in excess of one-half hour a portion of the first mixture with a gamma glutamyltransferase substrate and a gamma glutamyl acceptor to produce a second mixture;
adding to the second mixture aqueous solutions of an acid, a nitrite source, a means for accepting excess nitrite, and a means for diazo coupling, in sufficient relative quantities to produce a colored final mixture;
and measuring the color intensity of the final mixture at a wavelength in the range of 475 to 600 nanometers, said color intensity being proportional to enzyme activity.
applying a fluid, whole blood sample or fluid, hemolytic sample to a means for absorbent support;
drying the blood sample on the means for absorbent support to produce a dried blood sample;
dissolving the GGT contained in the dried blood sample by combining a quantity of the dried blood sample with a means for solubilizing the dried blood sample to produce a first mixture such that the maximum dilution of the fluid blood sample volume in the solubilizing means is about 1:60;
reacting for a time in excess of one-half hour a portion of the first mixture with a gamma glutamyltransferase substrate and a gamma glutamyl acceptor to produce a second mixture;
adding to the second mixture aqueous solutions of an acid, a nitrite source, a means for accepting excess nitrite, and a means for diazo coupling, in sufficient relative quantities to produce a colored final mixture;
and measuring the color intensity of the final mixture at a wavelength in the range of 475 to 600 nanometers, said color intensity being proportional to enzyme activity.
2. The method of claim 1 wherein the means for absorbent support is selected from the group consisting of cellulose fiber, glass, fritted glass, cotton fiber, paper, and diatomaceous earth.
3. The method of claim 1 wherein the means for solubilizing is selected from the group consisting of water, saline, buffered saline, and buffered water.
4. The method of claim 1 wherein the means for solubilizing includes a non-ionic detergent.
5. The method of claim 1 wherein the first mixture is agitated or sonicated.
6. The method of claim 1 wherein the acid is selected from the group consisting of phosphoric, citric, formic, boric, succinic, hydrochloric and acetic acids.
7. The method of claim 1 wherein the nitrite source is selected from the group consisting of sodium nitrite and potassium nitrite.
8. The method of claim 1 wherein the gamma glutamyltransferase substrate is selected from the group consisting of (gamma-L-glutamyl)-p-nitroanilide, and (gamma-L-glutamyl)-3-carboxy-p-nitroanilide.
9. The method of claim 1 wherein the means for accepting excess nitrite is selected from the group consisting of ammonium sulfamate and sulfamic acid.
10. The method of claim 1 wherein the means for diazo coupling is selected from the group consisting of N-(1-naphthyl) ethylenediamine dihydrochloride, 1-Naphthylamine, 2-Naphthylamine, 1-amino-5-Naphthol, 2-amino-5-Naphthol, and 1-amino-8-Naphthol.
11. A method of assaying the activity of gamma glutamyltransferase in a sample of whole blood which comprises:
reacting for a time in excess of one-half hour whole blood with a gamma glutamyltransferase substrate and a gamma glutamyl acceptor to produce a mixture;
adding to the mixture aqueous solution of an acid, a nitrite source, a means for accepting excess nitrite, and a means for diazo coupling, in sufficient relative quantities to produce a colored final mixture; and measuring the color intensity of the final mixture at a wavelength in the range of 475 to 600 nanometers, said color intensity being proportional to enzyme activity.
reacting for a time in excess of one-half hour whole blood with a gamma glutamyltransferase substrate and a gamma glutamyl acceptor to produce a mixture;
adding to the mixture aqueous solution of an acid, a nitrite source, a means for accepting excess nitrite, and a means for diazo coupling, in sufficient relative quantities to produce a colored final mixture; and measuring the color intensity of the final mixture at a wavelength in the range of 475 to 600 nanometers, said color intensity being proportional to enzyme activity.
12. The method of claim 11 wherein the gamma glutamyltransferase substrate is selected from the group consistingof(gamma-L-glutamyl)-p-nitroanilide,and(gamma-L-glutamyl)-3-carboxy-nitroanilide.
13. The method of claim 11 wherein the acid is selected from the group consisting of phosphoric, citric, formic, succinic, hydrochloric and acetic acids.
14. The method of claim 11 wherein the nitrite source is selected from the group consisting of sodium nitrite and potassium nitrite.
15. The method of claim 11 wherein the means for accepting excess nitrite is selected from the group consisting of ammonium sulfamate and sulfamic acid.
16. The method of claim 11 wherein the means for diazo coupling is selected from the group consisting of N-(1-naphthyl) ethylenediamine dihydrochloride, 1-Naphthylamine, 2-Naphthylamine, 1-amino-5-Naphthol, 2-amino-5-Naphthol, and 1-amino-8-Naphthol.
17
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2016704 CA2016704C (en) | 1990-05-16 | 1990-05-16 | Apparatus and assay method for gamma glutamyltransferase (ggt) in liquid and dried whole blood |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2016704 CA2016704C (en) | 1990-05-16 | 1990-05-16 | Apparatus and assay method for gamma glutamyltransferase (ggt) in liquid and dried whole blood |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2016704A1 CA2016704A1 (en) | 1991-11-16 |
| CA2016704C true CA2016704C (en) | 1996-03-12 |
Family
ID=4144978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2016704 Expired - Fee Related CA2016704C (en) | 1990-05-16 | 1990-05-16 | Apparatus and assay method for gamma glutamyltransferase (ggt) in liquid and dried whole blood |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2016704C (en) |
-
1990
- 1990-05-16 CA CA 2016704 patent/CA2016704C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2016704A1 (en) | 1991-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0171150B1 (en) | Method and apparatus for assaying with optional reagent quality control | |
| Viets et al. | Determination of serum protein concentration in nanoliter blood samples using fluorescamine or o-phthalaldehyde | |
| US6242207B1 (en) | Diagnostic compositions and devices utilizing same | |
| US4615972A (en) | Stabilization of indicators for detecting enzyme activity | |
| CA1303495C (en) | Use of immobilized biotinylated receptor in test device, kit and method for determining a ligand | |
| CN110632297A (en) | Immunoassay kit and determination method and preparation method thereof | |
| JPH11246593A (en) | Protection of protein and its analogue | |
| WO1989004485A1 (en) | Immunoassay utilizing formazan-prelabeled reactants | |
| US4748115A (en) | Substrate formulation in 2-amino-2-methyl-1-propanol buffer for alkaline phosphatase assays | |
| JPS6071957A (en) | Method of promoting immune reaction by ultrasonic treatment | |
| US5096812A (en) | Assay method for gamma glutamyltransferase (GGT) in liquid blood and dried blood | |
| EP0134953A2 (en) | Multilayer analytical element | |
| NO780822L (en) | PEROXYDASE DETERMINATION. | |
| US5188938A (en) | Enzyme quantitation wicking assay | |
| US4119401A (en) | Total bilirubin assay | |
| FI96723B (en) | Test kit for the determination of enzymes and method of analysis | |
| CA2016704C (en) | Apparatus and assay method for gamma glutamyltransferase (ggt) in liquid and dried whole blood | |
| JPH03251764A (en) | Buffering cleaning composition, test kit and method of its use | |
| JPH0646893A (en) | Analyte measuring method and measuring means | |
| EP1000358B1 (en) | Pre-stained 3,3',5,5'-tetramethylbenzidine substrates for the detection of enzyme activity | |
| US4030885A (en) | Bilirubin determination | |
| Penney et al. | Polycarbonate membranes: a novel surface for solid-phase determinations with utility in field format serological assays | |
| EP0376707B1 (en) | Enzyme quantitation wicking assay | |
| US20040121416A1 (en) | Assay | |
| JPH03218465A (en) | Production of syphilis diagnostic reagent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |